Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-12

Study Completion Date

2021-08-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Major cardiovascular events are greatest in liver transplant recipients with sustained post-transplantation diabetes1. However, the optimal A1c target after transplantation has not been studied. The objective is to understand the optimal A1c target post liver and combined liver and kidney transplant. Strict A1c control will improve mortality and cardiovascular risk post liver and combined liver and kidney transplant and improve complications post liver and combined liver and kidney transplant.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hyperglycemia and (Pre)Diabetes in Pediatric Renal and Liver Transplantation.

NCT05464043

Diabetes Mellitus Risk

COMPLETED NA

Impact of Glycemic Control After Reperfusion on Acute Kidney Injury in Living Donor Liver Transplantation

NCT06320730

Acute Kidney Injury Hyperglycemia Hypoglycemia +1 more

COMPLETED

Pancreatic Islet Cell Transplantation After Kidney Transplantation - A Novel Approach to Immunosupression

NCT03047200

Islet Cell Transplantation Type 1 Diabetes

WITHDRAWN PHASE1

Prospective Controlled Study of Posttransplant Diabetes

NCT00006331

Diabetes Mellitus Kidney Failure

UNKNOWN

NAFLD Among Patients With Chronic Kidney Disease and the Effect of Kidney Transplantation

NCT03866421

Non-Alcoholic Fatty Liver Disease Chronic Kidney Diseases PreDiabetes +1 more

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Major cardiovascular events are greatest in liver transplant recipients with sustained post-transplantation diabetes. However, the optimal A1c target after transplantation has not been studied. The objective is to understand the optimal A1c target post liver and combined liver and kidney transplant. Strict A1c control will improve mortality and cardiovascular risk post liver and combined liver and kidney transplant and improve complications post liver and combined liver and kidney transplant.

Strict blood sugar control in non-transplant patients with diabetes mellitus has shown unfavorable results in previous studies. However, no optimal A1c level has been studied in liver and combined liver and kidney transplant patients. Furthermore, guidelines for A1c target post-transplant are of expert opinion.

The primary objective is to assess the impact of hemoglobin A1c on all-cause mortality among patients with diabetes mellitus undergoing liver or combined liver and kidney transplantation between 2008 to 2018. The second objective is to assess the impact of hemoglobin A1c on complications post liver or combined liver and kidney transplantation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Liver Transplant; Complications Kidney Transplant Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

hemoglobin A1c

The hemoglobin A1c test (A1c) screens for, helps diagnose, and monitors diabetes and prediabetes.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients 18 years old or older in the United States with diabetes undergoing or post liver and combined liver and kidney transplant from January 2008 to December 2018.